Kidneys in heart failure: Impact of flozins

Stompór, Tomasz; Winiarska, Agata

doi:10.33963/v.kp.97844

Cited by 4 publications

(1 citation statement)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sodium-glucose cotransporter type 2 inhibitors (SGL-T2i) act by preventing sodium and glucose reabsorption from the kidney's proximal tubules [4,5]. This process indirectly influences many pathways, resulting in a variety of consequences in the body, including decreased vascular inflammation, generation of reactive oxygen species, and improved endothelial function via lowering vascular stiffness [1,2].…”

Section: Introductionmentioning

confidence: 99%

Effects of SGLT2 inhibitors on right ventricular function in heart failure patients: Updated meta-analysis of the current literature

Cinar,

Saylik,

Cicek

et al. 2024

Pol Heart J

View full text Add to dashboard Cite

Background: There is some discrepancy in current studies concerning the effect of sodium-glucose cotransporter type 2 inhibitors (SGLT2i) on right ventricular (RV) functions in heart failure (HF) patients. Hence, this meta-analysis was focused on determining the impact of SGLT2i on RV functions in such individuals.Material and methods: Two independent investigators searched PubMed, Google Scholar, and the Cochrane Library for articles of interest. To analyze heterogeneity, Higgins' I 2 as well as prediction intervals and Egger's test were used to assess heterogeneity. The Newcastle-Ottawa standard ratings approach was used to assess the quality of observational studies. The ROBINS-I risk of bias algorithm was used to assess bias risks of randomized studies.Results: This meta-analysis evaluated 8 studies in total. Over the follow-up time frame, patients who used SGLT2i had substantially lower systolic pulmonary artery pressure and higher tricuspid annular plane systolic excursion values (mean difference [MD] = -5.23 MD = 1.47 [1.01; 1.93]; P <0.01, respectively). There was no significant difference in RVS' values between follow-up and baseline (MD = 1.54 [-0.19; 3.26]; P = 0.08). However, as compared to the baseline period, fractional area contraction values were substantially larger at the end of the follow-up (MD = 5.52 [4.23; 6.82]; P <0.01). Conclusion:To the best of our knowledge, this is the first meta-analysis assessing the impact of SGLT2i on RV function in HF patients. Our findings suggest that SGLT2i may improve RV performance in HF patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of SGLT2 inhibitors on right ventricular function in heart failure patients: Updated meta-analysis of the current literature

Cinar,

Saylik,

Cicek

et al. 2024

Pol Heart J

View full text Add to dashboard Cite

show abstract

Comparison of the pharmacovigilance signals of cardiac and renal adverse events associated with sacubitril/valsartan and valsartan alone based on the FAERS database

Chen,

Li,

Zhou

et al. 2024

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Benefits of sacubitril/valsartan administration and physical training in cardiac rehabilitation: current trends and bibliometric analysis of the years 2015-2024

Iovanovici,

Dogaru,

Nistor – Cseppento

et al. 2024

Balneo and PRM Research Journal

View full text Add to dashboard Cite

Introduction. Heart failure, with its economic and social burden and increasing incidence in the general population, is a global problem. Since 2015, a new class of drugs with angiotensin and neprilysin re-ceptor inhibitory action, namely the combination of sacubitril and valsartan (S/V), has been introduced in the treatment of HF. The study aimed to perform a bibliometric analysis of the available knowledge and assess research trends through quantitative analysis of the literature related to the use of S/V and physical training in HF. Methods. In the study, we used the Web of Science database, period 2015-January 2024. The data obtained was processed with Vos viewer and Microsoft Excel. The results obtained and their interpretation provided an overview of the most relevant and prolific journals, countries, authors, and organizations. Conclusion. After marketing approval, the publication trend was upward until 2023, when the number of publica-tions decreased significantly. Our study shows that although the number of publications de-creased, updates of treatment guidelines were published, and a significant number of articles supporting the benefits of S/V treatment in chronic HF (with reduced or preserved ejection frac-tion) but also in acute forms were published. Although the number of articles on cardiac rehabilitation is low, this is highlighted in treatment guidelines and studies have emerged assessing the reasons why patients do not follow a cardiac rehabilitation programme. Cardiac rehabilitation is important for its physiological benefits: improving VO2max, myocardial blood flow and endothelial function. Health policies should be put in place to raise awareness of the importance of cardiac rehabilitation, including distances to a rehabilitation centre. Keywords: sacubitril/valsartan; heart failure; cardiac rehabilitation; bibliometric analysis

show abstract

Kidneys in heart failure: Impact of flozins

Cited by 4 publications

References 92 publications

Effects of SGLT2 inhibitors on right ventricular function in heart failure patients: Updated meta-analysis of the current literature

Effects of SGLT2 inhibitors on right ventricular function in heart failure patients: Updated meta-analysis of the current literature

Comparison of the pharmacovigilance signals of cardiac and renal adverse events associated with sacubitril/valsartan and valsartan alone based on the FAERS database

Benefits of sacubitril/valsartan administration and physical training in cardiac rehabilitation: current trends and bibliometric analysis of the years 2015-2024

Contact Info

Product

Resources

About